Antikoagulation bei Vorhofflimmern – Dabigatran, Rivaroxaban oder Apixaban – die Qual der Wahl?

Abstract

New oral anticoagulation agents (NOACs) have definitively widened the existing spectrum of antithrombotic prophylaxis and therapy. NOACs (dabigatran etexilate, rivaroxaban, apixaban) can be given at fixed doses without coagulation monitoring. They show additional advantages in comparison with the mainly used vitamin K antagonists. Oral anticoagulation with NOACs has to be initiated and monitored carefully and patient- and disease-specific factors have to be taken into account. This article summarizes published clinical trial data related to dabigatran, apixaban and rivaroxaban. We will discuss special aspects and further more how to manage emergency situations associated with the NOACs.

• Literatur

• 1 Ruff CT, Giugliano RP, Antman EM et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). AHJ 2010; 160: 635-641 DOI: 10.1016/j.ahj.2010.06.042.
• 2 Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annual review of medicine 2011; 62: 41-57 DOI: 10.1146/annurev-med-062209-095159.
• 3 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEJM 2009; 361: 1139-1151 DOI: 10.1056/NEJMoa0905561.
• 4 Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. NEJM 2011; 365: 981-992 DOI: 10.1056/NEJMoa1107039.
• 5 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEJM 2011; 365: 883-891 DOI: 10.1056/NEJMoa1009638.
• 6 Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. NEJM 2011; 364: 806-817 DOI: 10.1056/NEJMoa1007432.
• 7 Uchino KHAV. Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402 DOI: 10.1001/archinternmed.2011.1666.
• 8 Hohnloser SH, Oldgren J, Yang S et al. Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation 2012; 125: 669-676 DOI: 10.1161/circulationaha.111.055970.
• 9 Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372 DOI: 10.1161/CIRCULATIONAHA.110.004747.
• 10 Boehringer Ingelheim. Fachinformation Pradaxa 150 mg Hartkapseln. 2012
• 11 HealthCare B. Fachinformation des Arzneimittel-Kompendiums der Schweiz: Xareltro. 2012
• 12 Fachinformation ELIQUIS 2,5 mg Filmtabletten. 2011
• 13 Lip GY, Larsen TB, Skjoth F et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Card 2012; 60: 738-746 DOI: 10.1016/j.jacc.2012.03.019.
• 14 Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747 DOI: 10.1093/eurheartj/ehs253.
• 15 Komocsi A, Vorobcsuk A, Kehl D et al. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 1537-1545 DOI: 10.1001/archinternmed.2012.4026.
• 16 Mega JL, Braunwald E, Murphy SA et al. Rivaroxaban in Patients Stabilized after a ST-Elevation Myocardial Infarction: Results from the ATLAS ACS 2-TIMI 51 Trial. J Am Coll Card 2013; DOI: 10.1016/j.jacc.2013.01.066.
• 17 Lip GY, Durrani OM, Roldan V et al. Peri-operative management of ophthalmic patients taking antithrombotic therapy. Int J Clin Practice 2011; 65: 361-371 DOI: 10.1111/j.1742-1241.2010.02538.x.
• 18 Dewilde WJ, Oirbans T, Verheugt FW et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115 DOI: 10.1016/S0140-6736(12)62177-1.
• 19 Steiner T. Neue direkte orale Antikoagulanzien: Was im Notfall zu beachten ist. Dtsch Arztebl International 2012; 109: 1928-1930
• 20 Österreichische Gesellschaft für Laboratoriumsmedizin und Klinische Chemie. Neue Orale Antikoagulantien. 2013 http://www.oeglmkc.at/oak (27.02.2013)
• 21 BfARM – Bundesinstitut für Arzneimittel und Medizinprodukte. Hinweise zum Umgang mit Blutungen unter Dabigatran (Pradaxa). 2012